Discovery of Highly Potent and Selective Pan-Aurora Kinase Inhibitors with Enhanced in Vivo Antitumor Therapeutic Index
- 1 March 2012
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (7) , 3250-3260
Abstract
Serine/threonine protein kinases Aurora A, B, and C play essential roles in cell mitosis and cytokinesis. Currently a number of Aurora kinase inhibitors with different isoform selectivities are being evaluated in the clinic. Herein we report the discovery and characterization of 21c (AC014) and 21i (AC081), two structurally novel, potent, kinome-selective pan-Aurora inhibitors. In the human colon cancer cell line HCT-116, both compounds potently inhibit histone H3 phosphorylation and cell proliferation while inducing 8N polyploidy. Both compounds administered intravenously on intermittent schedules displayed potent and durable antitumor activity in a nude rat HCT-116 tumor xenograft model and exhibited good in vivo tolerability. Taken together, these data support further development of both 21c and 21i as potential therapeutic agents for the treatment of solid tumors and hematological malignancies.Keywords
This publication has 21 references indexed in Scilit:
- GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft modelsMolecular Cancer Therapeutics, 2009
- Aurora kinase inhibitors in preclinical and clinical testingExpert Opinion on Investigational Drugs, 2009
- Discovery and Development of Aurora Kinase Inhibitors as Anticancer AgentsJournal of Medicinal Chemistry, 2009
- Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cellsLeukemia & Lymphoma, 2008
- Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinaseProceedings of the National Academy of Sciences, 2007
- Aurora B expression correlates with aggressive behaviour in glioblastoma multiformeJournal of Clinical Pathology, 2007
- MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutationBlood, 2006
- Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinaseFEBS Letters, 2005
- Inhibition of Aurora B Kinase Blocks Chromosome Segregation, Overrides the Spindle Checkpoint, and Perturbs Microtubule Dynamics in MitosisCurrent Biology, 2002
- A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancersThe EMBO Journal, 1998